טוען...

Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients – Early Results of a Phase II Trial

Glioblastoma Multiforme (GBM) is an aggressive primary brain neoplasm with dismal prognosis. Based on successful phase III trials, 60 Gy involved-field radiotherapy in 30 fractions over 6 weeks [Standard radiation therapy (RT)] with concurrent and adjuvant temozolomide is currently the standard of c...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Floyd, Scott R., Kasper, Ekkehard M., Uhlmann, Erik J., Fonkem, Ekokobe, Wong, Eric T., Mahadevan, Anand
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2012
נושאים:	Oncology
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3472503/ https://ncbi.nlm.nih.gov/pubmed/23087896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2012.00122
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients – Early Results of a Phase II Trial

פריטים דומים